Table 5

EORTC QLQ-BR23 mean scores (SE) at each time point
CR & TT at T0 CR at T1 TT at T1 CR at T2 TT at T2 CR at T3 TT at T3 CR at T4 TT at T4 CR at T5 TT at T5
n=121 n=62 n=59 n=62 n=59 n=50 n=51 n=30 n=36 n=16 n=18
arm symptoms 24,33 21,00 (2,50) 18,07 (2,32) 21,24 (2,82) 18,01 (2,08) 22,02 (3,73) 26,33 (4,27) 19,89 (5,10) 19,96 (4,40) 11,14 (5,76) 18,78 (6,49)
breast symptoms 20,94 33,30 a (2,78) 29,57 (2,74) 23,67 (2,58) 24,10 (2,35) 17,99 (3,17) 15,94 (2,52) 14,55 (4,24) 12,60 (3,30) 6,87 (5,63) 16,77 (4,99)
body image 73,35 69,60 (2,14) 70,62 (2,49) 73,21 (2,48) 77,80 (2,55) 74,74 (3,67) 77,51 (2,87) 73,62 (5,76) 78,40 (4,93) 74,91 (7,02) 79,08 (7,36)
future perspective 53,44 57,33 (3,64) 51,02 (3,44) 58,36 (3,38) 58,62 (3,26) 61,78 (4,03) 65,44 (3,53) 64,55 (5,84) 64,55 (6,27) 59,69 (7,59) 68,03 (10,08)
systemic treatment side effects 14,64 22,50 (1,87) 25,81a (2,83) 22,52 (2,06) 21,21 (2,88) 18,01 (2,20) 17,88 (2,57) 19,40 (3,19) 13,20 (2,95) 17,62 (4,80) 15,24 (4,28)
n=21 n=22 n=26 n=16 n=20 n=8 n=10 n=8 n=6 n=3 n=3
upset by hair loss 34,92 48,25 a (8,16) 27,51 (9,26) 23,81 a (11,11) 40,48 a (5,56) 46,02 a (11,10) 28,25 a (16,33) 1,62 a (0,00) 23,81 (29,40) 34,92 a (0,00) 34,92 a (0,00)
n=104 n=53 n=50 n=53 n=53 n=42 n=45 n=26 n=30 n=13 n=15
sexual functioning 23,85 21,02 (2,68) 23,52 (3,45) 24,48 (3,04) 22,60 (3,36) 24,65 (3,50) 24,59 (2,90) 21,85 (4,44) 27,19 (3,61) 25,14 (6,92) 21,63 (5,36)
n=61 n=23 n=23 n=29 n=32 n=24 n=29 n=15 n=19 n=8 n=9
sexual enjoyment 55,74 53,98 (5,39) 47,40 (3,31) 48,16 (5,77) 50,61 (5,45) 61,29 a (4,86) 49,94 (4,98) 64,07 (5,98) 48,59 (5,16) 62,40 a (6,67) 46,21 (9,52)

a Indicates more or equal to ten-point difference from previous time point.

T0: baseline, T1: last day RT, T2: 3 months post-RT, T3: 1 year post-RT, T4: 2 years post-RT, T5: 3 years post-RT.

Versmessen et al.

Versmessen et al. BMC Cancer 2012 12:495   doi:10.1186/1471-2407-12-495

Open Data